Aldeyra Therapeutics (ALDX) Competitors $4.81 -0.18 (-3.61%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$4.87 +0.06 (+1.25%) As of 08/1/2025 05:19 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ALDX vs. NTLA, PHVS, CVAC, CDTX, PAHC, CALT, AUPH, ELVN, GPCR, and BGMShould you be buying Aldeyra Therapeutics stock or one of its competitors? The main competitors of Aldeyra Therapeutics include Intellia Therapeutics (NTLA), Pharvaris (PHVS), CureVac (CVAC), Cidara Therapeutics (CDTX), Phibro Animal Health (PAHC), Calliditas Therapeutics AB (publ) (CALT), Aurinia Pharmaceuticals (AUPH), Enliven Therapeutics (ELVN), Structure Therapeutics (GPCR), and BGM Group (BGM). These companies are all part of the "pharmaceutical products" industry. Aldeyra Therapeutics vs. Its Competitors Intellia Therapeutics Pharvaris CureVac Cidara Therapeutics Phibro Animal Health Calliditas Therapeutics AB (publ) Aurinia Pharmaceuticals Enliven Therapeutics Structure Therapeutics BGM Group Intellia Therapeutics (NASDAQ:NTLA) and Aldeyra Therapeutics (NASDAQ:ALDX) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, earnings, analyst recommendations, valuation, institutional ownership, dividends, risk and media sentiment. Do insiders & institutionals have more ownership in NTLA or ALDX? 88.8% of Intellia Therapeutics shares are owned by institutional investors. Comparatively, 59.7% of Aldeyra Therapeutics shares are owned by institutional investors. 3.1% of Intellia Therapeutics shares are owned by company insiders. Comparatively, 9.6% of Aldeyra Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Do analysts recommend NTLA or ALDX? Intellia Therapeutics presently has a consensus price target of $33.37, indicating a potential upside of 190.41%. Aldeyra Therapeutics has a consensus price target of $9.50, indicating a potential upside of 97.51%. Given Intellia Therapeutics' higher probable upside, research analysts plainly believe Intellia Therapeutics is more favorable than Aldeyra Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Intellia Therapeutics 1 Sell rating(s) 6 Hold rating(s) 12 Buy rating(s) 1 Strong Buy rating(s) 2.65Aldeyra Therapeutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has more risk and volatility, NTLA or ALDX? Intellia Therapeutics has a beta of 2.31, indicating that its stock price is 131% more volatile than the S&P 500. Comparatively, Aldeyra Therapeutics has a beta of 0.9, indicating that its stock price is 10% less volatile than the S&P 500. Which has stronger valuation & earnings, NTLA or ALDX? Aldeyra Therapeutics has lower revenue, but higher earnings than Intellia Therapeutics. Aldeyra Therapeutics is trading at a lower price-to-earnings ratio than Intellia Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioIntellia Therapeutics$57.88M20.56-$519.02M-$5.23-2.20Aldeyra TherapeuticsN/AN/A-$55.85M-$0.97-4.96 Is NTLA or ALDX more profitable? Aldeyra Therapeutics has a net margin of 0.00% compared to Intellia Therapeutics' net margin of -1,154.10%. Intellia Therapeutics' return on equity of -56.06% beat Aldeyra Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Intellia Therapeutics-1,154.10% -56.06% -44.25% Aldeyra Therapeutics N/A -72.58%-52.32% Does the media prefer NTLA or ALDX? In the previous week, Intellia Therapeutics had 8 more articles in the media than Aldeyra Therapeutics. MarketBeat recorded 9 mentions for Intellia Therapeutics and 1 mentions for Aldeyra Therapeutics. Intellia Therapeutics' average media sentiment score of 0.73 beat Aldeyra Therapeutics' score of 0.00 indicating that Intellia Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Intellia Therapeutics 3 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Aldeyra Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral SummaryIntellia Therapeutics beats Aldeyra Therapeutics on 11 of the 16 factors compared between the two stocks. Get Aldeyra Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ALDX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ALDX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ALDX vs. The Competition Export to ExcelMetricAldeyra TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$298.88M$2.49B$5.48B$9.53BDividend YieldN/A1.81%4.73%4.09%P/E Ratio-4.968.9728.8623.83Price / SalesN/A433.83371.4466.13Price / CashN/A157.7635.4557.96Price / Book4.044.838.265.54Net Income-$55.85M$31.62M$3.25B$259.28M7 Day Performance-6.96%-5.28%-3.73%-4.67%1 Month Performance20.25%4.38%4.28%4.38%1 Year Performance36.84%-2.49%25.85%17.90% Aldeyra Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ALDXAldeyra Therapeutics1.4083 of 5 stars$4.81-3.6%$9.50+97.5%+29.6%$298.88MN/A-4.9610Upcoming EarningsNTLAIntellia Therapeutics4.583 of 5 stars$12.63+4.7%$33.37+164.2%-54.3%$1.25B$57.88M-2.41600News CoverageUpcoming EarningsGap DownHigh Trading VolumePHVSPharvaris1.7551 of 5 stars$23.84+2.5%$36.20+51.8%+25.5%$1.22BN/A-7.9230CVACCureVac4.4413 of 5 stars$5.40+0.2%$6.83+26.5%+51.1%$1.21B$579.18M5.87880News CoveragePositive NewsCDTXCidara Therapeutics2.8836 of 5 stars$57.05-4.9%$57.29+0.4%+389.1%$1.21B$1.27M-1.9490Upcoming EarningsHigh Trading VolumePAHCPhibro Animal Health4.1282 of 5 stars$29.14-0.9%$24.40-16.3%+41.1%$1.19B$1.02B37.361,940Positive NewsDividend AnnouncementCALTCalliditas Therapeutics AB (publ)N/A$40.00flatN/AN/A$1.19B$1.60B-21.62180AUPHAurinia Pharmaceuticals2.4838 of 5 stars$8.62-0.1%$11.50+33.4%+87.0%$1.17B$235.13M30.79300Trending NewsEarnings ReportAnalyst ForecastAnalyst RevisionELVNEnliven Therapeutics2.4628 of 5 stars$21.87-3.5%$41.20+88.4%-24.2%$1.11BN/A-11.3950GPCRStructure Therapeutics2.0457 of 5 stars$18.13-5.8%$76.17+320.1%-51.7%$1.10BN/A-20.84136News CoverageUpcoming EarningsBGMBGM GroupN/A$10.63-5.8%N/AN/A$1.10B$25.10M0.00298High Trading Volume Related Companies and Tools Related Companies NTLA Competitors PHVS Competitors CVAC Competitors CDTX Competitors PAHC Competitors CALT Competitors AUPH Competitors ELVN Competitors GPCR Competitors BGM Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ALDX) was last updated on 8/2/2025 by MarketBeat.com Staff From Our Partners379 passengers walked away from thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredMarket Crash Warning: How to Protect Your Wealth Before August 12thChina tariffs hit August 12—and experts warn a market meltdown may follow. A free guide from American Alter...American Alternative | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredWhy AMZN, GOOG, MSFT might destroy NVDAInvesting Legend Hints the End May be Near for These 3 Iconic Stocks Futurist Eric Fry say Amazon, Tesla an...InvestorPlace | SponsoredMicrosoft's Next Big Bet?Microsoft just broke ground on a revolutionary power system that could deliver virtually limitless, carbon-fre...Stansberry Research | SponsoredAlien rocks potentially worth trillions…It might look like just a weird rock—but it’s tied to a discovery 60 Minutes says could be worth up to $16 tri...Porter & Company | SponsoredTrump’s crypto advisor may have revealed the next big crypto opportunityWhile investors chase Bitcoin toward $100K, D.C. insiders are quietly loading up on something else. One of Tru...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aldeyra Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aldeyra Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
